News

Date

Title

19/12/2017

Lanthio Pharma and MorphoSys scientists publish lanthipeptide phage display in Nature Communications
19/05/2017

MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers
21/02/2017

MorphoSys’s Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study with Lanthipeptide MOR107
19/09/2016

Lanthio Pharma Expands Management Team: Axel Mescheder M.D. Appointed Chief Medical Officer (CMO) of MorphoSys’s Dutch Lanthipeptide Subsidiary
07/05/2015

MorphoSys Acquires Lanthio Pharma
21/11/2014

Lanthio Pharma Receives Gouden KIEM Award as Dutch Chemical Start-up of the Year
15/10/2014

MorphoSys Acquires Lanthipeptide Technology from Lanthio Pharma
18/06/2014

Lanthio Pharma announces change of CEO
21/05/2014

Lanthio Pharma receives Dutch Government loan of up to €3.6 million to develop novel therapy for lung fibrosis
01/09/2013

Lanthio Pharma receives European Grant
26/11/2012

Lanthio Pharma announces technology alliance with MorphoSys AG and secures series A financing
08/05/2012

Lanthio Pharma receives grants from Samenwerkingsverband Noord Nederland and province of Groningen
06/05/2012

Lanthio Pharma receives Eurostars grant
20/12/2012

Lanthio Pharma licenses lanthionine-stabilized Angiotensin agonistic peptide drug to Tarix Pharmaceuticals
01/12/2011

Lanthio Pharma appoints Bart Wuurman as CEO